• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
REGN

REGN

Regeneron Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD618.95

+16.03 (+2.66%)

Rating:A

Company Profile

CEO

Leonard S. Schleifer

IPO Date

1991-04-02

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$600.72

Prev. Close

$602.92

Day Low

$599.00

Day High

$623.44

52W Low

$476.49

52W High

$821.11

Market Cap

$63.77B

Volume

0.95M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

38.7%

Avg Negative

28.4%

Avg Neutral

33.1%

News Feed

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

globenewswire.com·5/28/2026·↑ positive

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

newsfilecorp.com·5/25/2026·↓ negative

Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud Allegations

newsfilecorp.com·5/25/2026·↑ positive

Here's Why Regeneron (REGN) is a Strong Value Stock

zacks.com·5/22/2026·↑ positive

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

globenewswire.com·5/22/2026·↑ positive

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

prnewswire.com·5/21/2026·↓ negative

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

globenewswire.com·5/21/2026·↑ positive

Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

globenewswire.com·5/21/2026·↓ negative

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud

businesswire.com·5/20/2026·↓ negative

Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B

zacks.com·5/19/2026·↑ positive